TELO

Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (TELO) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.8
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.7%
Price Return 12M -63.6%
Catalyst Signal 0.00
Market Cap $36.1M
TTM Revenue N/A
Price / Sales N/A
ROE -213.1%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.8) C (2.3) D+ (1.7) C+ (2.6) C (2.2)
2026-11-08 C+ (2.5) C- (1.9) C (2.3) C- (2.1) C+ (2.6) C (2.3)
2026-11-01 C+ (2.5) C- (1.9) C (2.5) C- (2.1) C+ (2.7) C (2.3)
2026-10-25 C+ (2.5) C- (1.9) C (2.4) C- (2.1) C+ (2.6) C (2.3)
2026-10-18 C+ (2.5) D+ (1.8) C (2.4) C+ (2.5) C+ (2.6) C (2.4)
Page 1 of 3